CISPLATIN NEPHROTOXICITY - A SUMMARY OF PREVENTATIVE INTERVENTIONS

被引：33

作者：

FINLEY, RS ^{[1
]}

FORTNER, CL ^{[1
]}

GROVE, WR ^{[1
]}

机构：

[1] NCI,DCT,CTEP,INVEST DRUG BRANCH,DRUG MANAGEMENT & AUTHORIZAT SECT,BETHESDA,MD 20205

来源：

DRUG INTELLIGENCE & CLINICAL PHARMACY | 1985年 / 19卷 / 05期

关键词：

D O I：

10.1177/106002808501900505

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：362 / 367

页数：6

共 47 条

[11] GONZALEZVITALE JC, 1977, CANCER, V39, P1362, DOI 10.1002/1097-0142(197704)39:4<1362::AID-CNCR2820390403>3.0.CO
[12] 2-N
[13] HAYES DM, 1977, CANCER, V39, P1372, DOI 10.1002/1097-0142(197704)39:4<1372::AID-CNCR2820390404>3.0.CO
[14] 2-J
[15] INTRAPERITONEAL CISPLATIN WITH SYSTEMIC THIOSULFATE PROTECTION
HOWELL, SB
PFEIFLE, CL
WUNG, WE
OLSHEN, RA
LUCAS, WE
YON, JL
GREEN, M
[J]. ANNALS OF INTERNAL MEDICINE, 1982, 97 (06) : 845 - 851
[16] HOWELL SB, 1980, CANCER TREAT REP, V64, P611
[17] THE CLINICAL-APPLICATION OF CHRONOBIOLOGY TO ONCOLOGY
HRUSHESKY, WJM
[J]. AMERICAN JOURNAL OF ANATOMY, 1983, 168 (04): : 519 - 542
[18] HRUSHESKY WJM, 1983, P AM SOC CLIN ONCOL, V3, P27
[19] KOVACH JS, 1973, CANCER CHEMOTH REP 1, V57, P357
[20] LEGHA S, 1984, P AN M AM SOC CLIN, V3, P37